A5007947157- Lung Cancer Treatments and Mutations
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Cancer Genomics and Diagnostics
- Ovarian cancer diagnosis and treatment
- Cancer Diagnosis and Treatment
- Head and Neck Cancer Studies
- HER2/EGFR in Cancer Research
- Hemoglobinopathies and Related Disorders
- PI3K/AKT/mTOR signaling in cancer
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
- Nuclear Structure and Function
- Heparin-Induced Thrombocytopenia and Thrombosis
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Central Venous Catheters and Hemodialysis
The University of Texas MD Anderson Cancer Center
2016-2025
Comprehensive Cancer Centers of Nevada
2023-2025
Oregon Health & Science University
2020-2025
Aberdeen Royal Infirmary
2025
NHS Grampian
2025
University of Aberdeen
2025
Touro University Nevada
2023-2024
University of Nevada, Las Vegas
2023-2024
Touro College
2024
Center for Brooklyn History
2023
Abstract Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond ICT. To date, the genomic underpinnings primary resistance ICT remain elusive. Here, we performed immunogenomic analysis data from TCGA and trials anti-PD-1/PD-L1 therapy, with particular focus on homozygous deletion 9p21.3 (9p21 loss), one most frequent defects occurring in ~13% all cancers. We demonstrate that 9p21 loss confers “cold”...
DNA polymerase epsilon is critical to proofreading and replication. Mutations in
Cobalamin deficiency (CD) due to pernicious anemia (PA) leads hyperhomocystinemia, a risk factor for thrombosis. However, the clinical presentations and outcomes of hyperhomocystinemia-associated thrombosis (HAT) are not fully understood. We undertook literature search using PUBMED, SCOPUS WEB OF SCIENCE databases terms "pernicious AND thrombosis", embolism", thromboembolism", "autoimmune gastritis thromboembolism" through January 2024 reviewed published literature. Our aim was illustrate...
118 Background: Fruquintinib is a novel cancer therapy that was recently approved by the US FDA as third-line treatment for metastatic colorectal (mCRC). It works inhibiting vascular endothelial growth factor receptors, leads to blocking of angiogenesis which essential tumor proliferation. Close monitoring always crucial in order promptly detect and manage any adverse events. This study aims assess risk hemorrhagic VTE events patients with GI cancers treated fruquintinib. Methods: A...
119 Background: Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors which impedes angiogenesis associated with tumor growth. On November 8th, 2023, the US FDA approved fruquintinib for use as third-line treatment metastatic colorectal cancer (mCRC). With introduction novel therapies, monitoring adverse events critical. This meta-analysis aims to assess risk hypertension (HTN) and proteinuria in patients GI cancers treated fruquintinib. Methods: We conducted...
117 Background: Fruquintinib is a selective inhibitor of vascular endothelial growth factor receptors 1, 2, and 3 blocks the angiogenesis associated with tumor proliferation. Recently, US FDA approved fruquintinib as third-line treatment for metastatic colorectal cancer (mCRC). As any other novel therapies, adverse events are always concern all patients should be monitored in order to early detect appropriately treat events. This meta-analysis aims assess risk HFSR or PPE syndrome GI cancers...
"HSR25-143: Meta-Analysis of Phase 3 Randomized Controlled Trials to Evaluate the Incidence Systemic Toxicities in Patients With Relapsed/Refractory Multiple Myeloma Treated Belantamab Mafodotin" published on 28 Mar 2025 by National Comprehensive Cancer Network.
"HSR25-150: Meta-Analysis of Randomized Controlled Trials (RCTs) to Evaluate the Incidence Health-Related Quality Life (HRQOL) Events in Patients with Primary Advanced or Recurrent Endometrial Cancer Treated With First-Line Immunochemotherapy" published on 28 Mar 2025 by National Comprehensive Network.
"HSR25-152: Incidence of Hematologic Adverse Events in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Treated Amivantamab: A Meta-Analysis Phase III Randomized Controlled Trials" published on 28 Mar 2025 by National Comprehensive Network.